(Press-News.org) ANDOVER, Mass. - March 9, 2015 - DeuteRx, LLC, is a research and development-focused biotechnology company dedicated to improving racemic small molecule marketed drugs and drug candidates intended for patients across multiple therapeutic indications. Today, DeuteRx announced the discovery of a method for the in vivo stabilization and differentiation of the individual enantiomers of selected thalidomide analogs. The method is described in The Proceedings of the National Academy of Science (PNAS), entitled: "Differentiation of antiinflammatory and antitumorigenic properties of stabilized enantiomers of thalidomide analogs."
"Using our 'deuterium-enabled chiral switching' (DECS) platform, we enable the testing and development of the single, preferred enantiomer of certain drugs and drug-candidates that are currently developed or marketed as racemic mixtures (two mirror-image compounds or enantiomers). Historically, many stable, single enantiomer drugs have demonstrated improved therapeutic properties such as improved efficacy or reduced side effects over the parent racemic mixture. However, numerous drugs are still developed and marketed with racemic active ingredients because the enantiomers are chemically unstable and rapidly interconvert in vivo," said Sheila DeWitt, Ph.D., President & Chief Executive Officer of DeuteRx. "We have discovered and are developing stabilized enantiomers for several classes of compounds by replacing the exchangeable hydrogen at the chiral center with deuterium."
"Dr. DeWitt and her team have pioneered a novel approach to 'chiral switching', a successful and profitable strategy that initially emerged in the 1990s to develop the preferred, single, but stable enantiomer from a mixture of two stable enantiomers, resulting in many blockbuster drugs including Lexapro®, Lunesta®, Levaquin®, and Nexium®" said Timothy Barberich, Founder, Former Chairman, President & CEO to Sepracor (currently Sunovion Pharmaceuticals, Inc.) and advisor to DeuteRx.
In the publication, DeuteRx describes application of DECS to two thalidomide analogs, including CC-122, a compound currently in human clinical trials for hematological cancers and solid tumors. DeuteRx further shows that the in vitro antiinflammatory and in vivo antitumorigenic activity, in a mouse xenograft model of multiple myeloma, is due almost exclusively to the stabilized (-)-enantiomer of CC-122.
DeuteRx has eight issued U.S. patents with composition of matter claims encompassing deuterium-enriched enantiomers based on known racemic active ingredients. Additional pending patent applications by DeuteRx include claims to deuterium-enriched enantiomers for at least eleven families of thalidomide analogs, including CC-122.
INFORMATION:
About DeuteRx, LLC
DeuteRx is pioneering 'deuterium-enabled chiral switching' (DECS), a revolutionary approach to improve racemic small molecule marketed drugs and drug candidates intended for patients across multiple therapeutic indications. Numerous drugs are still developed and marketed with as racemic mixtures (two mirror-image compounds or enantiomers) because the enantiomers are chemically unstable and rapidly interconvert in vivo. To date, DeuteRx has demonstrated the use of DECS to stabilize the enantiomers of many racemic active ingredients including bupropion, donepezil, inolitazone, pioglitazone, prasugrel, CC-11006, CC-122, and MSDC-0160. DeuteRx's prioritized single enantiomer product assets are DRX-065 for nonalcoholic steatohepatitis (NASH), DRX-254 for multiple myeloma, DRX-195 for pediatric sickle cell disease, and DRX-184 for CNS disorders.
DeuteRx, LLC is a Boston-based biotechnology company founded in December 2012 as a spin-out company from Deuteria Pharmaceuticals, Inc. Deuteria Pharmaceuticals, Inc. was sold to a major biopharmaceutical company in December 2012.
http://www.deuterx.com
Lexapro® is a registered trademark of Forest Pharmaceuticals, Inc.
Lunesta® is a registered trademark of Sunovion Pharmaceuticals Inc.
Levaquin® is a registered trademark of Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Nexium® is a registered trademark of AstraZeneca Pharmaceuticals, LP.
Media Contact:
Hunter Marshall
MacDougall Biomedical Communications
650-342-1000
hmarshall@macbiocom.com
Capping and regulating CEO payments, including performance bonuses, could help make companies more profitable in the long term, new research has found.
According to modeling by Dr Peter Cebon at the University of Melbourne in Australia and Dr Benjamin Hermalin from the University of California, Berkeley, reliance on performance bonuses - which are often $7-10 AUD million per year for top Australian CEOs - can lead executives to pursue poor strategies, including being too focused on short term gains.
The model also showed that if bonuses are restricted, CEOs and boards ...
The paper summed the progress of the alternating EM field technique for earthquake monitoring and prediction after 1966 when Xingtai earthquake in Hebei province occurred, expounded the theoretical basement on electromagnetic field for this method, outlined new developed CSELF technique and the experimental examples and the study using satellite EM technologies, and introduced the new data processing and data mining techniques used for massive data (big data).
The study, entitled "Advances in alternating electromagnetic field data processing for earthquake monitoring ...
The level of vitamin D in our blood should neither be too high nor to low. Scientists from the University of Copenhagen are the first in the world to show that there is a connection between high levels of vitamin D and cardiovascular deaths.
In terms of public health, a lack of vitamin D has long been a focal point. Several studies have shown that too low levels can prove detrimental to our health. However, new research from the University of Copenhagen reveals, for the first time, that also too high levels of vitamin D in our blood is connected to an increased risk of ...
This news release is available in German. It has not yet been possible to measure the gravitational waves predicted by Einstein's theory of general relativity. They are so weak that they get lost in the noise of the measurements. But thanks to the latest simulations of the merging of binary neutron star systems, the structure of the sought-after signals is now known. As a team of German and Japanese theoretical astrophysicists reports in the Editor's choice of the current edition of the scientific journal "Physical Review D", gravitational waves have a characteristic ...
Researchers at the University of Birmingham believe that a new method of genetically engineering immune cells could lead to improved treatment of Nasopharyngeal carcinoma (NPC) patients.
The research, published in Cancer Immunology Research, explains how the team were able to create immune cells (T-cells) that use the presence of the Epstein-Barr virus to combat NPC.
NPC develops in the upper part of the throat known as the nasopharynx, which connects the back of your nose to the back of your mouth.
This particular cancer is unusually common throughout Southeast ...
A new approach to care for patients with advanced HIV in Tanzania and Zambia, combining community support and screening for a type of meningitis, has reduced deaths by 28%.
The research, published in The Lancet, suggests that a simple low-cost intervention could be an effective approach to reducing HIV-related deaths in Africa.
Researchers from the National Institute of Medical Research Tanzania, the University Teaching Hospital in Zambia, St Georges University of London and the London School of Hygiene & Tropical Medicine conducted a randomised trial of 1,999 HIV ...
One of the biggest unknowns in understanding the effects of climate change today is the melting rate of glacial ice in Antarctica. Scientists agree rising atmospheric and ocean temperatures could destabilize these ice sheets, but there is uncertainty about how fast they will lose ice.
The West Antarctic Ice Sheet is of particular concern to scientists because it contains enough ice to raise global sea level by up to 16 feet, and its physical configuration makes it susceptible to melting by warm ocean water. Recent studies have suggested that the collapse of certain parts ...
A team of scientists led by astronomers at the University of Bonn discovered an unusual phenomenon in the centre of the Milky Way: They detected about 20 rotating dust and gas discs in each cluster hosting exceptionally large and hot stars. The existence of these discs in the presence of the destructive UV radiation field of their massive neighbours came as a surprise. The science team is pondering how these rotating discs are able to withstand evaporation under these extreme conditions. The results are published in the most recent edition of the journal „Astronomy ...
A new study from the University of Warwick is calling for more UK compulsory regulation of devices used in hip replacements to reduce the need for further traumatic and expensive surgery.
In a paper published today in the British Medical Journal, a team from Warwick Medical School looked at ten year revision rates for five of the most commonly used hip replacement devices. This means the number of devices that had to be replaced within 10 years of the original surgery.
The team found the revision rates for these devices were less than 5% but warned many other devices ...
Genes linked with a greater risk of developing autism may also be associated with higher intelligence, a study suggests.
Researchers have found new evidence linking genetic factors associated with autism to better cognitive ability in people who do not have the condition.
The relationship between autism and intelligence is not clear, researchers say. Although up to 70 per cent of individuals with autism have an intellectual disability, some people with the disorder have relatively well-preserved, or even higher than average, non-verbal intelligence, the team says. ...
